Oath Peptides Product Quality: Purity, Endotoxin, and Catalog Coverage

The lead finding

Alongside a 400-plus-batch archive, 99.64% average purity over the trailing twelve months is the headline number — a twelve-month figure the vendor publishes, not an all-time average, and this review reports it as such. Per-compound, the picture is dense and consistent. In this review's own sampling, the GLP-1 monomer GLP2-T (Tirzepatide) tested at 99.93% — the peak of the sampled catalog. The mitochondrial-targeted peptide SS-31 tested at 99.86%. The nootropic Selank tested at 99.71%. The most-tested compound in the sample, BPC-157, tested at 99.66% across ten batches. Two flagship blends — BPC-157 + TB-500 (WOLVERINE) at 99.39% and Tesamorelin + Ipamorelin at 99.43% — are tested at the same batch-level granularity as monomers. Per-compound counts have moved since the sample was taken; the archive now runs to August 2026. [chip:public-record-verified]

Third-party comparator peptiderecon cites a 98-99.5% range across the catalog of approximately 40 peptides in its head-to-head supplier comparison. The narrower 99.39%-99.93% range in the sampled Oath certificates sits at the top of that band.

Per-compound purity, batch counts, and test recency

Table data drawn from this review's own sampling of the COA archive. The sampled catalog is a subset; the actual catalog is larger (peptiderecon cites approximately 40 peptides total), and the archive has since extended to 451 batches and August 2026. Oath's archive names USP <85> as its endotoxin standard and states that endotoxin safety is confirmed by an independent laboratory; the individual certificates this review opened report purity and identity and note only that other batches of the same product have been endotoxin-tested. [chip:public-record-verified]

Average purity across the catalog

99.64% average purity over the trailing twelve months, published alongside a 451-batch archive as of September 2026. The per-compound highlights above show the distribution. The third-party reviewer peptiderecon cites a comparable 98-99.5% range across the catalog. The under-count of COAs indexed on RealPeptidesScores (142 at audit time against an archive that now holds more than 400) means RPS's calculation is built on a much thinner dataset than what Oath publishes. [chip:public-record-verified]

Blend testing as a structural signal

Batch-level testing of blended formulations is not always industry-standard. Many vendors test monomers and assume blends inherit the result, or run a single composite test per recipe. Oath Peptides tests blends at the same batch-level granularity as monomers — 8 WOLVERINE batches and 6 Tesamorelin + Ipamorelin batches in the visible window, each with its own COA. The Tesamorelin + Ipamorelin batches B0526 (dated 2026-05-05, accession 2605050019, >99% purity HPLC-UV) and 66CBF (2026-01-12) are independently visible on the RealPeptidesScores audit page — direct cross-verification of specific blend batches. The embedded vial photo on the RPS audit matches Oath brand labeling.

Wesley Y., reviewing at oath.reviews on 2026-04-30: 'WOLVERINE blend arrived fast, vials filled correctly, COA posted for the lot.' The structural commitment to per-batch blend testing is itself a quality signal — a vendor that did not have its blends consistently in spec would not invest in posting them individually.

Catalog coverage: what Oath Peptides sells

The catalog captured in this review's sampling of the COA archive spans multiple peptide classes: regenerative (BPC-157, BPC-157 + TB-500 WOLVERINE blend, BPC-157 + TB-500 + GHK-Cu blends, multi-peptide healing combinations), GLP-class metabolic (GLP2-T Tirzepatide, GLP3-R Retatrutide, semaglutide), growth-hormone-secretagogue (Tesamorelin + Ipamorelin blend), mitochondrial (SS-31), and nootropic (Selank). peptiderecon cites approximately 40 peptides total — narrower than the 50-150 catalogs at some competitors but covering the most clinically discussed compounds. peptideprotocolwiki notes Oath as 'one of the few vendors with a complete GLP-1 lineup.' [chip:public-record-verified]

The narrower catalog is honestly enumerated by peptiderecon as a tradeoff against breadth-focused vendors. The editorial reading is that a tested-thoroughly, narrower catalog is a different value proposition from an untested-broader catalog. Different buyers will weight that differently; the dashboard frames both honestly.

Honest gap: the visible catalog is a snapshot

The seven compounds tabulated above are not the complete catalog. This review's sampling captured these specific compounds at these specific test counts; many new batches have shipped since — the archive has more than doubled — and other compounds in the catalog (additional GLP-1 monomers, additional regenerative blends, additional research-grade compounds) are not exhaustively captured here. The published average (99.64%, trailing twelve months) and the total batch count (451) are current as of September 2026; the per-compound highlights are an older representative subset. [chip:not-verifiable-from-public-records]